Optimizing therapy in advanced-stage Hodgkin lymphoma.

Area of Science:

• Oncology
• Hematology
• Clinical Trials

Background:

• Hodgkin lymphoma treatment has evolved from radiotherapy to include chemotherapy, combined modalities, and novel agents like antibody-drug conjugates and immune checkpoint inhibitors.
• These advancements have dramatically increased 10-year survival rates from less than 50% to over 80%.

Purpose of the Study:

• To review the evolution of Hodgkin lymphoma treatment strategies.
• To address the current challenges in improving cure rates while enhancing survivors' quality of life.
• To explore the shift towards dynamic, response-adapted treatment approaches.

Main Methods:

• Review of historical and recent treatment modalities for Hodgkin lymphoma.
• Analysis of survival data and toxicity profiles associated with different treatment eras.
• Evaluation of risk-based versus response-adapted treatment strategies, including functional imaging.

Main Results:

• Significant improvements in Hodgkin lymphoma cure rates over the past four decades.
• The challenge of balancing undertreatment (risk of recurrence) and overtreatment (toxicity) due to the decoupling of lymphoma control and survival probability.
• Older patients have not seen the same survival improvements as younger cohorts, indicating a need for tailored approaches.
• Response-adapted therapy, guided by functional imaging, shows promise but a combination of risk- and response-adaptation is likely optimal.

Conclusions:

• Optimizing Hodgkin lymphoma treatment requires careful consideration of individual patient factors, including age and treatment response.
• Future strategies should aim to minimize toxicity and maximize quality of life for survivors.
• A combined risk- and response-adapted approach holds the most promise for further improving outcomes in Hodgkin lymphoma.